Open an account

Prokidney

PROK · NASDAQ

$1.44+$0.045 (+3.23%)TodayMarket closed ·
Prev close $1.40

About PROK

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 231 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Employees
231
Headquarters
Winston-Salem, North Carolina
Listed
Jun 30, 2021
Sector
Health Care
Industry
Biotechnology
Website
prokidney.com

PROK key statistics

Market cap
435.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.28M
Volume
1.49M
Open price
$1.40
High today
$1.51
Low today
$1.35
52 Week high
$3.48
52 Week low
$1.30

Prokidney (PROK) at a glance

As of Oct 20, 2026, Prokidney (PROK) shares are priced at $1.44, giving the company a market cap of 435.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.35 and $1.51. The current price is 6.7% above the day's low and 4.6% below its high.

Volume so far is 1.49M shares, in line with the average of 1.28M shares a day.

Over the past year Prokidney has ranged from $1.30 to $3.48, and now sits 6% of the way up that range.

Prokidney met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.15 per share against an estimate of -$0.1435.

The average analyst price target is $6.38, 342.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $6.38
Low
$1.01
Now
$1.44
High
$12.60

PROK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 9.6% on average.

  1. Q3 FY24: reported -$0.14 per share against an estimate of -$0.1489
  2. Q4 FY24: reported -$0.17 per share against an estimate of -$0.1515
  3. Q1 FY25: reported -$0.13 per share against an estimate of -$0.1607
  4. Q2 FY25: reported -$0.13 per share against an estimate of -$0.1469
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.1346
  6. Q4 FY25: reported -$0.14 per share against an estimate of -$0.124
  7. Q1 FY26: reported -$0.14 per share against an estimate of -$0.1408
  8. Q2 FY26: reported -$0.15 per share against an estimate of -$0.1435

PROK news

  • Press releasePRNewswire

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

  • Press releasePRNewswire

    Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

  • Chris Katje

    SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC

  • Chris Katje

    Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14%

  • Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy

  • Henry Khederian

    ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results

  • Avi Kapoor

    Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

  • Mohd Haider

    ProKidney Stock Shoots Up Over 8% After Hours After Staggering 515% Rally On Wednesday

Similar companies

Companies in the same industry as Prokidney

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.